相关实验视频

Updated: Jan 16, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

在驱动突变阴性黑色素瘤中使用基于RNA的定多重聚合酶链反应来检测融合基因

Tokimasa Hida¹, Masashi Idogawa², Sayuri Sato¹

¹Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Pigment cell & melanoma research

|October 1, 2025

概括

在缺乏常见突变的日本黑色素瘤中发现了融合基因,提供了新的治疗点. 这种基于RNA的方法可以检测驱动负性黑色素瘤中可操作的基因融合.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

先进的黑色素瘤治疗依赖于免疫检查点抑制剂 (ICI) 和向疗法.
目前的治疗方法在非白人群体中常见的状和粘膜黑色素瘤的有效性有限.
这些黑色素瘤亚型往往缺乏像BRAF这样的主要驱动突变,需要替代治疗策略.

研究的目的:

在缺乏常见驱动突变 (BRAF,RAS,NF1,KIT) 的日本黑色素瘤中检测融合基因.
评估基于RNA的多重聚合酶链反应 (AMP) 的实用性,用于在临床样本中识别融合基因.

主要方法:

来自14个日本黑色素瘤瘤的RNA分析,其中大部分是甲固定型氨酸嵌入式.
使用定制的Archer FUSIONPlex面板进行基于RNA的融合检测.
开发并验证了定多重PCR (AMP) 工作流程,包括质量控制.

主要成果:

从80%的分析样本中成功生成了库.
确定了两个框架内融合基因:MAD1L1::BRAF和CIC::MEGF8 (17%的病例).
MAD1L1::BRAF保留了BRAF激酶域,这表明潜在的MEK抑制剂向. CIC::MEGF8是一种新型的融合,可能导致转录失调.

结论:

基于RNA的融合检测是驱动负性黑色素瘤的一个有价值的方法.
融合基因代表了针对特定黑色素瘤亚型的有希望的可操作的治疗点.
描述的AMP工作流适用于用于融合基因鉴定的临床样本.

关键词:

这是一种CIC蛋白质.这是一个RNARNARNARNARNA.这是基因融合,基因融合.黑色素瘤是一种黑色素瘤.原型原蛋白蛋白质B-raf 的原型原蛋白.

更多相关视频

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

相关概念视频

RACE - Rapid Amplification of cDNA Ends

RACE - Rapid Amplification of cDNA Ends

Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific...